Literature DB >> 16782941

Half dose verteporfin PDT for central serous chorioretinopathy.

J M Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16782941      PMCID： PMC1857128          DOI： 10.1136/bjo.2006.093328

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  9 in total

1.  Verteporfin therapy for choroidal hemangioma: a long-term follow-up.

Authors:  Stephan Michels; Rike Michels; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Retina       Date:  2005-09       Impact factor: 4.256

2.  Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity.

Authors:  F D Verbraak; R O Schlingemann; M D de Smet; J E E Keunen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02-28       Impact factor: 3.117

3.  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Authors:  Mohammad Azab; David S Boyer; Neil M Bressler; Susan B Bressler; Ilona Cihelkova; Young Hao; Ilkka Immonen; Jennifer I Lim; Ugo Menchini; Joel Naor; Michael J Potter; Al Reaves; Philip J Rosenfeld; Jason S Slakter; Peter Soucek; H Andrew Strong; Andrea Wenkstern; Xiang Yao Su; Yit C Yang
Journal:  Arch Ophthalmol       Date:  2005-04

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Influence of treatment parameters on selectivity of verteporfin therapy.

Authors:  Stephan Michels; Fabian Hansmann; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

6.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  Chronic central serous chorioretinopathy: photodynamic therapy.

Authors:  Mehryar Taban; David S Boyer; Edgar L Thomas; Mehran Taban
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

8.  Photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Chiara M Eandi; Luca Ventre; Roberta C Rigault de la Longrais; Federico M Grignolo
Journal:  Retina       Date:  2003-12       Impact factor: 4.256

9.  Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Lawrence A Yannuzzi; Jason S Slakter; Nicole E Gross; Richard F Spaide; Danielle L L Costa; Sheau J Huang; James M Klancnik; Alexander Aizman
Journal:  Retina       Date:  2003-06       Impact factor: 4.256
  9 in total
  9 in total

1.  Combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-06       Impact factor: 3.117

2.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

3.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-30       Impact factor: 3.117

4.  Role of Avastin in management of central serous chorioretinopathy.

Authors:  Shaaban A Mehany; Ahmad M Shawkat; Mohamed F Sayed; Khaled M Mourad
Journal:  Saudi J Ophthalmol       Date:  2010-10-04

5.  Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy.

Authors:  Francesco Semeraro; Mario R Romano; Paola Danzi; Francesco Morescalchi; Ciro Costagliola
Journal:  Jpn J Ophthalmol       Date:  2012-08-23       Impact factor: 2.447

6.  Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.

Authors:  Gholam A Peyman; Michael Tsipursky; Nariman Nassiri; Mandi Conway
Journal:  J Ophthalmic Vis Res       Date:  2011-07

7.  Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.

Authors:  Myrte B Breukink; Susan M Downes; Giuseppe Querques; Elon H C van Dijk; Anneke I den Hollander; Rocio Blanco-Garavito; Jan E E Keunen; Eric H Souied; Robert E MacLaren; Carel B Hoyng; Sascha Fauser; Camiel J F Boon
Journal:  Trials       Date:  2015-09-21       Impact factor: 2.279

8.  Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity.

Authors:  Mayuka Hayashida; Akiko Miki; Shunichiro Nakai; Wataru Matsumiya; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura
Journal:  PLoS One       Date:  2020-10-12       Impact factor: 3.240

9.  Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity.

Authors:  Aya Chubachi; Akiko Miki; Mayuka Hayashida; Mari Sakamoto; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.